Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
10
×
boston blog main
boston top stories
clinical trials
national top stories
san francisco blog main
boston
deals
san francisco top stories
cancer drugs
fda
new york blog main
new york top stories
cancer
investing
third rock ventures
biotech ipos
blackstone group
david goldstein
depression
epilepsy
essential tremor
europe blog main
hepatitis b
ipo
kiran reddy
major depressive disorder
national
perimenopausal depression
praxis precision medicines
revolution medicines
roche
san francisco
sanofi
startups
steven petrou
the column group
venture capital
What
research
10
×
medicines
biotech
drug
ipo
new
cancer
drugs
aims
ceo
companies
disease
gene
genetic
ipos
praxis
precision
proteins
revolution
stop
targets
therapeutics
way
abbvie
alex
alliance
announced
approach
arrival
backed
based
biotechs
black
called
cancer’s
caught
cause
causing
central
clinic
Language
unset
10
×
Current search:
research
×
unset
×
" national blog main "
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Pfizer Taps Insilico Medicine to Use AI for Drug Target Discovery
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further